Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates?

Breast J. 2012 Jan-Feb;18(1):23-7. doi: 10.1111/j.1524-4741.2011.01178.x. Epub 2011 Oct 21.

Abstract

Axillary node dissection (ALND) is the standard of care for patients who have a positive sentinel lymph node (SLN) on sentinel lymph node biopsy (SLNB). We sought to identify a low-risk patient population with positive SLN that may not need cALND. We analyzed SLNB for breast cancer at our institutions between 1999 and 2007. We identified 130 patients who had a positive SLN but did not undergo completion ALND. We evaluated clinical data, adjuvant treatment patterns and intermediate locoregional and distant events. The median patient age was 50; 19% had N0(i+) disease, 53% had micrometastatic (N1mi) disease, and 28% had macrometastasis. Eighty-eight percent of patients underwent radiation therapy; 66 patients (51%) had documented nodal radiation (of these 50 were treated with three fields and 14 with high tangents. Local recurrence in the breast occurred in two patients (2%) and nine patients (7%) developed distant metastases; there were no axillary/nodal recurrences. In this highly selected group of patients who had a positive SLNB but did not undergo cALND, we observed no axillary recurrences.

Publication types

  • Evaluation Study

MeSH terms

  • Axilla
  • Breast Neoplasms / pathology
  • Breast Neoplasms / radiotherapy
  • Breast Neoplasms / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Lymph Node Excision*
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Micrometastasis
  • Neoplasm Recurrence, Local
  • Prognosis
  • Retrospective Studies
  • Sentinel Lymph Node Biopsy*
  • Treatment Outcome